Immunogenicity and safety of hepatitis E vaccine in healthy hepatitis B surface antigen positive adults

• DOI: 10.4161/hv.25814
• Publication Date: 2013-08-16T16:25:04Z
• Authors: Ting Wu; Shou-Jie Huang; Feng-Cai Zhu; Xue-Feng Zhang; Xing Ai; Qiang Yan; Zhong-Ze Wang; Chang-Lin Yang; Han-Min Jiang; Xiao-Hui Liu; Meng Guo; Hai-Lian Du; Mun-Hon Ng; Jun Zhang; Ningshao Xia
• Keywords: Hepatitis B; Hepatitis A vaccine; Hepatitis B vaccine

A recombinant hepatitis E vaccine, Hecolin, has been proven safe and effective in healthy adults. As B surface antigen (HBsAg) positive individuals have a higher risk of poor prognosis after super-infection with virus (HEV), the safety immunogenicity Hecolin this population should be assessed. The present study is an extending analysis data from large randomized controlled clinical trial Hecolin. Healthy participants (n = 14,065) without current or previous evidence chronic liver disease were to receive placebo (hepatitis vaccine) donated their blood samples before vaccination subsequently over 31 mo. Most adverse events mild comparable between baseline (HBsAg). No vaccine-related serious reported. Rates HBsAg (+) (-) also both groups. Almost all group seroconverted anti-HEV one month full vaccination. antibody response rates levels similar (98.38%, 19.32 Wu/mL vs. 98.69%, 19.00 Wu/mL). two-year dynamics overlapped perfectly those participants. In conclusion, for adults very that general population.